Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

427.29USD
22 Jun 2018
Change (% chg)

$-10.98 (-2.51%)
Prev Close
$438.27
Open
$443.15
Day's High
$444.07
Day's Low
$426.99
Volume
1,042,972
Avg. Vol
692,351
52-wk High
$450.93
52-wk Low
$139.49

Chart for

About

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops,... (more)

Overall

Beta: 0.20
Market Cap(Mil.): $19,846.46
Shares Outstanding(Mil.): 44.48
Dividend: --
Yield (%): --

Financials

  ABMD.O Industry Sector
P/E (TTM): 149.79 37.70 33.54
EPS (TTM): 2.93 -- --
ROI: 22.69 8.01 13.09
ROE: 23.51 11.90 15.10

BRIEF-Abiomed Q4 GAAP EPS $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

May 03 2018

BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

May 03 2018

BRIEF-Abiomed Announces European Approval For Impella 5.5(Tm)

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage:

Apr 05 2018

BRIEF-Abiomed Announces European Approval (CE Marking) For Impella 5.5™

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5™ AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 04 2018

BRIEF-Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor

* ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR

Apr 02 2018

BRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer

* ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP

Mar 30 2018

Abiomed to pay $3.1 million to settle case over lavish doctor meals

BOSTON Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.

Mar 08 2018

UPDATE 2-Abiomed to pay $3.1 mln to settle case over lavish doctor meals

BOSTON, March 8 Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.

Mar 08 2018

BRIEF-Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals

* ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS Source text: (http://bit.ly/2G9t6b6) Further company coverage:

Mar 08 2018

Heart pump maker Abiomed settles U.S. kickback probe for $3.1 mln

BOSTON, March 8 Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. investigation into allegations that it sought to induce doctors into using a line of heart pumps it produced by buying them lavish meals.

Mar 08 2018

Earnings vs. Estimates